Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

In-depth proteomic analysis of paraffin-embedded tissue samples from colorectal cancer patients revealed TXNDC17 and SLC8A1 as key proteins associated with the disease

  • Montero-Calle, Ana
  • Garranzo Asensio, María
  • Povés, Carmen
  • Sanz, Rodrigo
  • Dziaková, Jana
  • Peláez-García, Alberto
  • Ríos, Vivian de los
  • Martínez-Useros, Javier
  • Fernandez-Aceñero, M. Jesús
  • Barderas, Rodrigo
19 p.-6 fig.-2 tab.-1 graph. abst., A deeper understanding of colorectal cancer (CRC) biology would help to identify specific early diagnostic markers. Here, we conducted quantitative proteomics on FFPE healthy, adenoma, and adenocarcinoma tissue samples from six stage I sporadic CRC patients to identify dysregulated proteins during early CRC development. Two independent quantitative 10-plex TMT experiments were separately performed. After protein extraction, trypsin digestion, and labeling, proteins were identified and quantified by using a Q Exactive mass spectrometer. A total of 2681 proteins were identified and quantified after data analysis and bioinformatics with MaxQuant and the R program. Among them, 284 and 280 proteins showed significant upregulation and downregulation (expression ratio ≥1.5 or ≤0.67, p-value ≤0.05), respectively, in adenoma and/or adenocarcinoma compared to healthy tissue. Ten dysregulated proteins were selected to study their role in CRC by WB, IHC, TMA, and ELISA using tissue and plasma samples from CRC patients, individuals with premalignant colorectal lesions (adenomas), and healthy individuals. In vitro loss-of-function cell-based assays and in vivo experiments using three CRC cell lines with different metastatic properties assessed the important roles of SLC8A1 and TXNDC17 in CRC and liver metastasis. Additionally, SLC8A1 and TXNDC17 protein levels in plasma possessed the diagnostic ability of early CRC stages., This work was supported by the financial support from PI20CIII/00019 and PI23CIII/00027 grants from the AES-ISCIII program cofounded by FEDER funds to R.B. The financial support provided by the European Innovation Council (EIC) through the EIC Pathfinder Open 2023 project (Grant No. 101130574) to R.B. is also acknowledged. The FPU predoctoral contract to A.M-C. was supported by the Spanish Ministerio de Educación, Cultura y Deporte., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Integrating immune library probing with structure-based computational design to develop potent neutralizing nanobodies against emerging SARS-CoV-2 variants

  • Cerdán, Lidia
  • Silva, Katixa
  • Rodríguez-Martín, Daniel
  • Pérez, Patricia
  • Noriega, María A
  • Esteban Martín, Ana
  • Gutiérrez-Adán, Alfonso
  • Margolles, Yago
  • Corbera, Juan A
  • Martín-Acebes, Miguel A.
  • García-Arriaza, Juan
  • Fernández-Recio, Juan
  • Fernández, Luis A.
  • Casasnovas, José M.
To generate antibodies (Abs) against SARS-CoV-2 emerging variants, we integrated multiple tools and engineered molecules with excellent neutralizing breadth and potency. Initially, the screening of an immune library identified a nanobody (Nb), termed Nb4, specific to the receptor-binding domain (RBD) of the Omicron BA.1 variant. A Nb4-derived heavy chain antibody (hcAb4) recognized the spike (S) of the Wuhan, Beta, Delta, Omicron BA.1, and BA.5 SARS-CoV-2 variants. A high-resolution crystal structure of the Nb4 variable (VHH) domain in complex with the SARS-CoV-2 RBD (Wuhan) defined the Nb4 binding mode and interface. The Nb4 VHH domain grasped the RBD and covered most of its outer face, including the core and the receptor-binding motif (RBM), which was consistent with hcAb4 blocking RBD binding to the SARS-CoV-2 receptor. In mouse models, a humanized hcAb4 showed therapeutic potential and prevented the replication of SARS-CoV-2 BA.1 virus in the lungs of the animals. In vitro, hcAb4 neutralized Wuhan, Beta, Delta, Omicron BA.1, and BA.5 viral variants, as well as the BQ.1.1 subvariant, but showed poor neutralization against the Omicron XBB.1.5. Structure-based computation of the RBD-Nb4 interface identified three Nb4 residues with a reduced contribution to the interaction with the XBB.1.5 RBD. Site-saturation mutagenesis of these residues resulted in two hcAb4 mutants with enhanced XBB.1.5 S binding and virus neutralization, further improved by mutant Nb4 trimers. This research highlights an approach that combines library screening, Nb engineering, and structure-based computational predictions for the generation of SARS-CoV-2 Omicron-specific Abs and their adaptation to emerging variants., The work was supported by the Ministerio de Ciencia, Innovación yUniversidades [202020E079, 202120E079, 202340E181, CNS2022-135511, PID2020-114481RB-I00, PID2022-143215OB-I00 andPLEC2021-007739]; NextGenerationEU [SGL 2103047, SGL 2103051and SGL 2103053]; HORIZON EUROPE Framework Programme[101130574-ALADDIN], Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Progress in engineered bacterial cancer therapies

  • Pico-Sánchez, Eva
  • Fernández, Luis Ángel
Engineered bacteria are emerging as powerful tools in the development of cancer therapies, driven by advances in synthetic biology and tumor immunology. These microbes preferentially colonize solid tumors, where they can deliver therapeutic agents directly to malignant cells and into the tumor microenvironment, inducing tumor cell death and activating robust anti-tumor immune responses. Current strategies include programming bacteria to secrete toxins, tumor-suppressor or pro-apoptotic proteins, and to mediate targeted intracellular delivery. Bacteria can also be engineered to sense tumor-specific metabolites and to adhere to tumor-associated cell surface antigens, further enhancing selectivity and safety. Engineered strains synergize with immunotherapies — including immune checkpoint inhibitors and chimeric antigen receptor-T cells — and can stimulate both innate and adaptive immune responses, even at distant metastatic sites. Here, we review recent progress in this field, with a focus on engineering strategies and their effectiveness in preclinical in vivo tumor models, and outline prospects for future developments and remaining challenges., This work was supported by grant PID2023-148228OB-I00 by MICIU/AEI/10.13039/501100011033 and FEDER, EU; and by Horizon-EIC-PathfinderOpen 101130574 from European Union., Peer reviewed, Sin experimentacion animal ni uso de NAMs